Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318733 · ClinicalTrials.gov registry record · Phase 3
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Phase 3 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
- 20
- Study locations
NCT01318733 is a Phase 3 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 449 participants, above the 224-participant average among 23 other Rosacea trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01318733, a Phase 3 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
Conditions Studied
Interventions
- DRUG CD07805/47 gel 0.5%
Study Locations (20)
North Carolina
- Metrolina Medical Research - Charlotte
- Dermatology, Laser & Vein Specialists of the Carolinas - Charlotte
- Wilmington Medical Research - Wilmington
- Piedmont Medical Research - Winston-Salem
Tennessee
- Rivergate Dermatology Clinical Research Center, PLLC - Goodlettsville
- East Tennessee Medical Research - Johnson City
- TriCities Medical Research - Kingsport
Colorado
- Cherry Creek Research, Inc - Denver
- Longmont Clinical PC - Longmont
Michigan
- Hamzavi Dermatology - Fort Gratiot
- Dermcenter PC- Somerset Skin Centre - Troy
California
- The Laser Institute for Dermatology - Santa Monica
Georgia
- Gwinnett Clinical Research Center, Inc - Snellville
Indiana
- Deaconess Clinic - Evansville
Kansas
- Compliant Clinical Research - Olathe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01318733
The ClinicalTrials.gov registry entry for NCT01318733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 23 other Rosacea trials with a reported enrollment target (100% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which CD07805/47 gel 0.5% is the first listed.
NCT01318733 reports 20 study locations spanning 13 distinct geographic areas - top geographies include North Carolina, Tennessee, Colorado.
Frequently Asked Questions
What is clinical trial NCT01318733 about?
NCT01318733 is a clinical study titled "Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT01318733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2011-03. Estimated completion is 2012-07.
What conditions does trial NCT01318733 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01318733?
The interventions under investigation include: CD07805/47 gel 0.5% (DRUG).
Who is sponsoring clinical trial NCT01318733?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01318733 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.